HIV protease inhibitors: immunological insights

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• Highly active antiretroviral therapy (HAART) significantly reduces human immunodeficiency virus (HIV) RNA levels and increases CD4 cell counts.
• Clinical improvement and reduced opportunistic infections are observed in patients receiving HAART.
• The origin and functional capacity of CD4 cells in HAART-treated patients warrant further investigation.

Purpose of the Study:

• To summarize current knowledge on immune reconstitution in HIV patients undergoing HAART.
• To explore changes in T cell populations, including naive and memory CD4 cells, and the T cell repertoire.
• To discuss the potential role of cytokines in facilitating immune reconstitution.

Main Methods:

• Review of preliminary data and studies available up to late 1997.
• Analysis of CD4 cell recirculation from lymphoid tissue to blood.
• Examination of changes in naive (CD45RA+, CD62L+) and memory (CD45RO+) CD4 cell counts.
• Assessment of T cell repertoire (Vbeta) alterations.
• Investigation into the role of cytokines in immune reconstitution.

Main Results:

• HAART leads to increased CD4 cell counts and decreased HIV RNA.
• Some studies show increases in memory CD4 cells followed by naive CD4 cells after HAART initiation.
• Naive CD4 cell increases may depend on pre-therapy levels; Vbeta subset disruptions may not be immediately corrected.
• Ongoing studies explore the relationship between cytokines and immune reconstitution.

Conclusions:

• HAART offers significant hope for partial immune reconstitution in HIV patients, particularly when initiated early.
• Future therapies may involve cytokines (e.g., interleukin-2), vaccinations, cellular replacement, or stem cell/bone marrow transplantation.